ArticleEuropean journal of public health2021
Cervical cancer testing among women aged 30-49 years in the WHO European Region.
Article in European journal of public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).British journal of cancer · 2026Article
- Adherence to Breast, Cervical, and Colorectal Cancer Screening Among Women in Spain: Evidence from the 2023 Spanish Health Survey.Healthcare (Basel, Switzerland) · 2026Article
- Primary healthcare providers' knowledge, attitudes, and practices regarding cancer screening recommendation and referral in Georgia, 2023.The European journal of general practice · 2025Article
- Article
- Emotional, Cognitive, and Social Factors Influencing Romanian Women's Intention to Undergo Cervical Cancer Screening: A Mixed-Method Study.Healthcare (Basel, Switzerland) · 2025Article
- Human Papillomavirus and Other Relevant Issues in Cervical Cancer Pathogenesis.International journal of molecular sciences · 2025Review
- Human Papilloma Virus Vaccination as a Strategy to Eliminate Cervical Cancer: Challenges and Opportunities.Vaccines · 2025Article
- Analysis of the global burden of cervical cancer in young women aged 15-44 years old.European journal of public health · 2024Article
- Observational
- Socioeconomic disparities in Papanicolaou test utilization in Western Iran.BMC public health · 2024Article
- Trends and Determinants in Uptake of Cervical Cancer Screening in Spain: An Analysis of National Surveys from 2017 and 2020.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundScreening programs play an important role in a comprehensive strategy to prevent cervical cancer, a leading cause of death among women of reproductive age. Unfortunately, there is a dearth of information about rates of cervical cancer testing, particularly in Eastern Europe and Central Asia where levels of cervical cancer are among the highest in the WHO European Region. The purpose of this article is to report on the lifetime prevalence of cervical cancer testing among females aged 30-49 years from across the WHO European region, and to describe high-level geographic and socioeconomic differences.
methodsWe used data from the European Health Information Survey and the WHO STEPwise approach to Surveillance survey to calculate the proportions of women who were tested for cervical cancer.
resultsThe percentage of tested women ranged from 11.7% in Azerbaijan to 98.4% in Finland, with the lowest percentages observed in Azerbaijan, Tajikistan and Uzbekistan. Testing was lower in Eastern Europe (compared to Western Europe), among low-income countries and among women with lower levels of education.
conclusionEffective cervical cancer screening programs are one part of a larger strategy, which must also include national scale-up of human papilloma virus vaccination, screening and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.